Predicting beta-2 microglobulin rebound after dialysis
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a protein called beta-2 microglobulin (β2M) changes after your dialysis session. It aims to better understand this protein's levels to help manage your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to make your own medical decisions.
- You have end-stage kidney disease and have been on regular hemodialysis for at least 3 months.
- You do not have an active infection (like a cold or flu) within the past 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a protein supplement during dialysis is safe and helps improve nutrition. You take the supplement during your usual dialysis sessions, and it may help you feel stronger and healthier.
This study measures how well a dialysis method called haemodiafiltration removes waste products from the blood, tracks how patients feel, and monitors sodium balance. It aims to improve treatment for people with kidney failure on dialysis.
This trial studies whether a blood test called delta C-cistatin can help doctors predict when patients can safely stop continuous kidney dialysis after acute kidney injury.
This study looks at whether two simple blood tests (D-dimer and CRP) can help predict heart problems in people on dialysis. If you join, they would check these markers in your blood and see if they relate to your heart health.
This study looks at how different types of dialysis affect salt stored in your tissues and your small blood vessels. It may help doctors understand how to improve dialysis treatments.
This study looks at blood samples from people with kidney problems to learn more about the condition and find better ways to treat it.
Hear when a new Renal Disease, End Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.